PLSec: A novel, liquid biomarker for HCC risk

Joseph W Franses; Irun Bhan; Andrew X Zhu

doi:10.1016/j.medj.2021.06.004

PLSec: A novel, liquid biomarker for HCC risk

Med. 2021 Jul 9;2(7):788-790. doi: 10.1016/j.medj.2021.06.004.

Authors

Joseph W Franses¹, Irun Bhan², Andrew X Zhu³

Affiliations

¹ Massachusetts General Hospital Division of Hematology-Oncology, Harvard Medical School, Boston, MA 02114, USA.
² Massachusetts General Hospital Division of Gastroenterology, Harvard Medical School, Boston, MA 02114, USA.
³ Massachusetts General Hospital Division of Hematology-Oncology, Harvard Medical School, Boston, MA 02114, USA; Jiahui International Cancer Center, Shanghai, China. Electronic address: [email protected].

PMID: 35590215
DOI: 10.1016/j.medj.2021.06.004

Abstract

Cirrhosis confers a variable risk of developing hepatocellular carcinoma (HCC), but the risk varies significantly depending upon ill-defined factors. In this issue of Med, Fujiwara et al.¹ use hepatic gene signatures and computational analysis to develop a streamlined, robust blood-based predictor of HCC risk in this population.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biomarkers
Carcinoma, Hepatocellular* / diagnosis
Humans
Liver Cirrhosis / diagnosis
Liver Neoplasms* / diagnosis

Substances

Biomarkers